methysergide

Trade name: sansert

Small moleculeapproved

Approved

Feb 12, 1962

Methysergide is an oral, synthetic ergot alkaloid, structurally related to the oxytocic agent methylergonovine and to the potent hallucinogen LSD. Methysergide is used prophylactically to reduce the frequency and intensity of severe vascular headaches. Although methysergide is an ergot alkaloid, it is a weak vasoconstrictor and oxytocic. Methysergide is a more potent antagonist of peripheral serotonin receptors than other ergot alkaloids. Methysergide is not just a 5HT2 antagonist, it is also a 5HT1 agonist. Although methysergide and sumatriptan both stimulate serotonin receptors centrally, methysergide is intended for prophylaxis while sumatriptan is indicated for treatment of an acute attack. Methysergide was approved by the FDA in 1962. Methysergide was formerly used for prophylaxis of cluster headaches/migraine headaches, but is no longer recommended due to retroperitoneal/retropulmonary fibrosis. — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 1 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Timeline

1960s

  1. Feb 12, 1962

    Novartis — Earliest FDA Approval

  2. Feb 12, 1962

    Novartis — NDA Secondary Org

  3. Feb 12, 1962

    Novartis — NDA Organization

Indications

Mechanism of action

Approval history

  • approvedPriority reviewFeb 12, 1962

Chemistry & pharmacology

Loading structure…

SMILES

CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4c3c(cn4C)C[C@H]2N(C)C1
Mol. weight
353.47 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Discontinued

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • 1-methyl-dextro-lysergic acid (+)-1-hydroxy-2-butylamide
  • 1-methyl-dextro-lysergic acid (+)-1-hydroxy-2-butylamide
  • 1-methyl-d-lysergic acid butanolamide
  • 1-methyl-d-lysergic acid butanolamide
  • 1-methyl-d-lysergic acid butanolamide
  • 1-methyllysergic acid butanolamide
  • 1-methyllysergic acid butanolamide
  • 1-methyllysergic acid butanolamide
  • 1-methyllysergic acid butanolamide tartrate, (r-(r*,r*))-(8beta)-isomer
  • 1-methylmethylergonovine
  • 1-methylmethylergonovine
  • (+)-9,10-didehydro-n-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8beta-carboxamide
  • (+)-9,10-didehydro-n-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8beta-carboxamide
  • 9,10-didehydro-n-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8-carboxamide
  • 9,10-didehydro-n-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8-carboxamide
  • deseril
  • deseril
  • deseril
  • deseril
  • deseril
  • deseril
  • methysergid
  • methysergide
  • methysergide
  • methysergide
  • methysergide
  • methysergide
  • methysergide
  • methysergide
  • methysergide maleate
  • methysergide maleate
  • methysergide maleate
  • methysergide maleate
  • methysergidum
  • methysergidum
  • metisergida
  • metisergida
  • metisergido
  • metisergido
  • n-(1-(hydroxymethyl)propyl)-1-methyl-dextro-(+)-lysergamide
  • n-(1-(hydroxymethyl)propyl)-1-methyl-dextro-(+)-lysergamide
  • (+)-n-(1-(hydroxymethyl)propyl)-1-methyl-d-lysergamide
  • (+)-n-(1-(hydroxymethyl)propyl)-1-methyl-d-lysergamide
  • sansert
  • sansert
  • sansert

Organizations

Marketing (2)

OrganizationOrg typeRelationshipDate
NovartisFor profitNDA2Feb 12, 1962
NovartisFor profitNDAFeb 12, 1962